Simvastatin Attenuates Doxorubicin-Induced Inflammation in Human Cardiomyocytes

Roberta Vitale1,2, Rosaria Margherita Rispoli1,2, Maria Carmela Di Marcantonio3

  • 1Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.

Biomedicines
|May 27, 2026
PubMed

Insights

Simvastatin (SIM) protects against Doxorubicin (Doxo)-induced cardiotoxicity by reducing oxidative stress and inflammation. This study shows SIM mitigates Doxo

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Doxorubicin (Doxo) chemotherapy causes cardiotoxicity, linked to oxidative stress, NF-κB activation, and NLRP3 inflammasome.
  • Identifying cardioprotective strategies is crucial in cardio-oncology.

Purpose of the Study:

  • To evaluate if Simvastatin (SIM) can attenuate Doxo-induced inflammatory responses and cardiotoxicity.
  • To investigate SIM's effects on key molecular pathways involved in Doxo cardiotoxicity.

Main Methods:

  • Human Cardiomyocyte (HCM) cells were pre-treated with SIM then co-exposed to SIM and Doxo.
  • Assessed nitric oxide (NO) production, iNOS expression, NF-κB signaling, pro-inflammatory cytokines (TNF-α, IL-6), NLRP3 inflammasome components (caspase-1, IL-1β, GSDMD), and Cx43/pCx43 levels.

Main Results:

  • SIM significantly reduced Doxo-induced NO release, iNOS expression, and NF-κB activation.
  • SIM attenuated pro-inflammatory cytokine production and NLRP3 inflammasome activation.
  • SIM decreased overexpression of Cx43 and pCx43, mitigating impaired cardiomyocyte communication.

Conclusions:

  • Simvastatin demonstrates multifaceted cardioprotection against Doxo-induced injury.
  • SIM targets interconnected inflammatory and pro-arrhythmic pathways, offering a potential therapeutic strategy in cardio-oncology.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...